claraᵀ™
Total mRNA Report

Complimentary webinar:

Almac's enhanced RNA-Seq reporting solution claraᵀ
- Simplifying complex biologies within the Hallmarks of Cancer.

On demand - click here

Time investment: under 30 mins.

ALMAC
Partnering to Advance Human Health

Almac's enhanced RNA-seq reporting solution clara^T – simplifying complex biologies within the Hallmarks of Cancer.

Webinar description

RNA Sequencing (RNA-seq) is an increasingly popular technology for biomarker discovery in cancer research. High-throughput RNA-seq produces large quantities of complex data that require computational bioinformatics pipelines to enable interpretation.

Almac Diagnostic Services has developed a unique reporting solution called clara^T* - A unique software-driven solution, classifying biologically relevant gene expression signatures into a comprehensive, easy-to-interpret report.

The clara^T report outputs include the entire study cohort and individual sample reports from Almac internally developed bioinformatics pipelines. clara^T reports on relevant public and proprietary gene expression signatures as well as single gene targets within the Hallmarks of Cancer using Almac's optimised RNA exome panel.

Benefits of clara^T:

- Maximises the understanding of your data set

- Provides readouts for the most relevant published gene expression signatures

- Classifies using the Hallmarks of Cancer for easy interpretation

- Interactive cohort and sample report

- Multiple signatures from a single tumour sample

- Cost effective solution, saving analysis time

Learn about the clara^T report:

- How the clara^T report was created
- The structure and layout of the clara^T report
- A detailed walk through of both the cohort and sample summaries
- How the clara^T report can support biomarker discovery and aid novel cancer research findings
- Case study: Utilising clara^T in a real world gene expression dataset for malignant melanoma

Speaker:

Dr Gemma Logan,
Senior Product Manager
Almac Diagnostic Services

Dr Gemma Logan is a Senior Product Manager within the internal Product Development team at Almac Diagnostic Services. Gemma studied Biomedical Science at Queen's University Belfast, leading to a PhD in Molecular Oncology before joining Almac Diagnostic Services in 2015.

Gemma's role focuses on managing the development and commercialisation activities for Almac Diagnostic Services new RNA based biomarker discovery solutions. In particular Gemma has liaised with multi-disciplinary teams to manage the product development and delivery of Almac's unique gene expression solution - clara^T Total mRNA Report, used to facilitate Pharma & Biotech clients in their biomarker development programmes.

*clara^T is for research use only (RUO) and is not to be used for diagnostic or prognostic purposes, including predicting responsiveness to a particular therapy.

Download Almac's complimentary webinar today

[Click here]

almacgroup.com

GET IN TOUCH

UK
Almac Group
19 Seagoe Industrial Estate
Craigavon
BT63 5UA
United Kingdom

US
Almac Group
4238 Technology Drive Durham
NC 27704
United States of America

diagnostics@almacgroup.com
+44 28 3833 7575

diagnostics@almacgroup.com
+1 (919) 479 8850

AM9027